Related Experiment Video
Updated: Mar 28, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model
Kejin Zhou1, Liem H Nguyen2, Jason B Miller1
1Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Dallas, TX 75390; Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX 75390;
Abstract:
RNA-based cancer therapies are hindered by the lack of delivery vehicles that avoid cancer-induced organ dysfunction, which exacerbates carrier toxicity. We address this issue by reporting modular degradable dendrimers that achieve the required combination of high potency to tumors and low hepatotoxicity to provide a pronounced survival benefit in an aggressive genetic cancer model. More than 1,500 dendrimers were synthesized using sequential, orthogonal reactions where ester degradability was systematically integrated with chemically diversified cores, peripheries, and generations. A lead dendrimer, 5A2-SC8, provided a broad therapeutic window: identified as potent [EC50 < 0.02 mg/kg siRNA against FVII (siFVII)] in dose-response experiments, and well tolerated in separate toxicity studies in chronically ill mice bearing MYC-driven tumors (>75 mg/kg dendrimer repeated dosing). Delivery of let-7 g microRNA (miRNA) mimic inhibited tumor growth and dramatically extended survival. Efficacy stemmed from a combination of a small RNA with the dendrimer's own negligible toxicity, therefore illuminating an underappreciated complication in treating cancer with RNA-based drugs.
Insights
New degradable dendrimers offer potent RNA delivery for cancer therapy, minimizing organ toxicity and improving survival in genetic cancer models. This breakthrough enhances RNA-based drug safety and efficacy.
Area of Science:
- Biotechnology
- Nanomedicine
- Cancer Therapeutics
Background:
- RNA-based cancer therapies face challenges due to delivery vehicles causing organ dysfunction and toxicity.
- Existing methods struggle to balance therapeutic potency with patient safety, particularly in complex cancer models.
Purpose of the Study:
- To develop modular, degradable dendrimers for effective RNA delivery in cancer treatment.
- To create a delivery system that minimizes hepatotoxicity while maximizing tumor potency.
- To improve survival rates in aggressive genetic cancer models using RNA therapeutics.
Main Methods:
- Synthesis of over 1,500 dendrimers using sequential, orthogonal reactions, integrating ester degradability with diverse chemical structures.
- Systematic evaluation of dendrimer properties, including potency (EC50 for siFVII) and toxicity in chronically ill mice with MYC-driven tumors.
- Administration of a let-7g microRNA (miRNA) mimic via a lead dendrimer (5A2-SC8) to assess therapeutic effects on tumor growth and survival.
Main Results:
- The lead dendrimer, 5A2-SC8, demonstrated high potency (EC50 < 0.02 mg/kg siFVII) and excellent tolerability (>75 mg/kg repeated dosing).
- Delivery of let-7g miRNA mimic using the dendrimer significantly inhibited tumor growth and extended survival in a genetic cancer model.
- The dendrimer exhibited negligible inherent toxicity, contributing to the overall therapeutic safety profile.
Conclusions:
- Modular degradable dendrimers represent a promising platform for safe and effective RNA delivery in cancer therapy.
- This approach addresses the critical issue of carrier toxicity and organ dysfunction associated with RNA-based treatments.
- The findings highlight the potential to overcome significant hurdles in translating RNA therapeutics for improved cancer patient outcomes.
